Literature DB >> 20460633

Integrins as target: first phase III trial launches, but questions remain.

Andrea Carter.   

Abstract

Mesh：

Substances：

Year:  2010        PMID： 20460633     DOI： 10.1093/jnci/djq186

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  18 in total

Review 1.  Integrins as therapeutic targets: lessons and opportunities.

Authors:  Dermot Cox; Marian Brennan; Niamh Moran
Journal:  Nat Rev Drug Discov       Date:  2010-10       Impact factor: 84.694

2.  Pharmacological Inhibition of β3 Integrin Reduces the Inflammatory Toxicities Caused by Oncolytic Adenovirus without Compromising Anticancer Activity.

Authors:  Ashley Browne; Laura A Tookman; Carin K Ingemarsdotter; Russell D Bouwman; Katrina Pirlo; Yaohe Wang; Iain A McNeish; Michelle Lockley
Journal:  Cancer Res       Date:  2015-05-14       Impact factor: 12.701

3.  Immunohistochemical analysis of integrins αvβ3, αvβ5 and α5β1, and their ligands, fibrinogen, fibronectin, osteopontin and vitronectin, in frozen sections of human oral head and neck squamous cell carcinomas.

Authors:  Eva-Maria Fabricius; Gustav-Paul Wildner; Ute Kruse-Boitschenko; Bodo Hoffmeister; Simon L Goodman; Jan-Dirk Raguse
Journal:  Exp Ther Med       Date:  2010-12-02       Impact factor: 2.447

4.  Beta1 integrin cytoplasmic tyrosines promote skin tumorigenesis independent of their phosphorylation.

Authors:  Alexander Meves; Tamar Geiger; Sara Zanivan; John DiGiovanni; Matthias Mann; Reinhard Fässler
Journal:  Proc Natl Acad Sci U S A       Date:  2011-08-29       Impact factor: 11.205

Review 5.  Brain invasion in meningiomas-clinical considerations and impact of neuropathological evaluation: a systematic review.

Authors:  Benjamin Brokinkel; Katharina Hess; Christian Mawrin
Journal:  Neuro Oncol       Date:  2017-10-01       Impact factor: 12.300

Review 6.  Tumor stroma as targets for cancer therapy.

Authors:  Jing Zhang; Jinsong Liu
Journal:  Pharmacol Ther       Date:  2012-10-12       Impact factor: 12.310

Review 7.  Current state of in vivo panning technologies: Designing specificity and affinity into the future of drug targeting.

Authors:  Heather H Gustafson; Audrey Olshefsky; Meilyn Sylvestre; Drew L Sellers; Suzie H Pun
Journal:  Adv Drug Deliv Rev       Date:  2018-06-28       Impact factor: 15.470

8.  Integrins and their ligands are expressed in non-small cell lung cancer but not correlated with parameters of disease progression.

Authors:  Christine Böger; Holger Kalthoff; Simon L Goodman; Hans-Michael Behrens; Christoph Röcken
Journal:  Virchows Arch       Date:  2013-11-26       Impact factor: 4.064

9.  Integrins αvβ3 and αvβ5 as prognostic, diagnostic, and therapeutic targets in gastric cancer.

Authors:  Christine Böger; Viktoria S Warneke; Hans-Michael Behrens; Holger Kalthoff; Simon L Goodman; Thomas Becker; Christoph Röcken
Journal:  Gastric Cancer       Date:  2014-10-15       Impact factor: 7.370

10.  Dynamic PET and Optical Imaging and Compartment Modeling using a Dual-labeled Cyclic RGD Peptide Probe.

Authors:  Lei Zhu; Ning Guo; Quanzheng Li; Ying Ma; Orit Jacboson; Seulki Lee; Hak Soo Choi; James R Mansfield; Gang Niu; Xiaoyuan Chen
Journal:  Theranostics       Date:  2012-08-06       Impact factor: 11.556
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.